CC-115 is a dual mammalian target of rapamycin (mTOR) kinase and DNA-PK inhibitor that demonstrated efficacy in CLL patient cells, inducing apoptosis and suppressing cellular proliferation, irrespective of ATM or TP53 mutations (68). Here, ATM is linked to B-cell chronic lymphocytic leukemia.